CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme
Status:
Unknown status
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Rationale:
In light of the demonstrated activity of anti-angiogenesis agents in rGBM, it is reasonable
to postulate that adding these agents to standard RT and chemotherapy in the up-front
management of newly diagnosed GBM may improve the clinical benefit. This study will examine
the safety and tolerability of adding CT-322 to the standard radiation therapy/temozolomide
(RT/TMZ) backbone of treatment for newly diagnosed GBM